AgenciesHyderabad headquartered healthcare services provider Yashoda Hospitals group on Friday announced that it has joined hands with the generic drugmaker to conduct clinical trials for oral administration of repurposed rheumatoid arthritis drug Molnupiravir for patients with mild and moderate Covid-19 symptoms.
Natco Pharma has recently received the nod of the Drug Controller General of India to conduct phase-3 clinical trials on Molnupiravir.
Yashoda Hospitals has emerged as the first hospital in India to be associated with Natco Pharma for the clinical trials on the critical anti-Covid-19 drug, said the hospital group’s medical director Lingaiah Amidalya.
“We hope that the trial is a success proving it to be a game-changer,” he said. “If patients can be treated with Molnupiravir in the mild stage of the disease, the transmission of Covid-19 can be controlled and further worsening of the disease can be prevented at large scale.”
Pre-clinical (animal) studies have found that Molnupiravir has remarkably reduced SARS-CoV-2 load and was found to have completely suppressed the spread of disease from animal to animal, and the virus multiplication development had stopped.
In a Phase-I clinical trial conducted in the United Kingdom, Molnupiravir was deemed to be safe and well tolerated up to 800 mg twice a day for 5 days in healthy trial subjects.
In the Phase-II clinical trials conducted in the United States, all patients who received Molnupiravir for 5 days were found to have a negative SARS-CoV-2 culture after the 5-day treatment duration, said the release.
Yashoda Hospitals said it will, as a part of Phase-III clinical trials, entail the Covid-19 patient volunteers to take 800 mg twice a day without being admitted in the hospital, since it is an OPD (out-patient department) based clinical trial, and have regular interactions with their physicians on day-5, day-10 and day-15 for their follow-up cycle at the hospital.
Natco Pharma has recently received the nod of the Drug Controller General of India to conduct phase-3 clinical trials on Molnupiravir.
Yashoda Hospitals has emerged as the first hospital in India to be associated with Natco Pharma for the clinical trials on the critical anti-Covid-19 drug, said the hospital group’s medical director Lingaiah Amidalya.
“We hope that the trial is a success proving it to be a game-changer,” he said. “If patients can be treated with Molnupiravir in the mild stage of the disease, the transmission of Covid-19 can be controlled and further worsening of the disease can be prevented at large scale.”
Pre-clinical (animal) studies have found that Molnupiravir has remarkably reduced SARS-CoV-2 load and was found to have completely suppressed the spread of disease from animal to animal, and the virus multiplication development had stopped.
In a Phase-I clinical trial conducted in the United Kingdom, Molnupiravir was deemed to be safe and well tolerated up to 800 mg twice a day for 5 days in healthy trial subjects.
In the Phase-II clinical trials conducted in the United States, all patients who received Molnupiravir for 5 days were found to have a negative SARS-CoV-2 culture after the 5-day treatment duration, said the release.
Yashoda Hospitals said it will, as a part of Phase-III clinical trials, entail the Covid-19 patient volunteers to take 800 mg twice a day without being admitted in the hospital, since it is an OPD (out-patient department) based clinical trial, and have regular interactions with their physicians on day-5, day-10 and day-15 for their follow-up cycle at the hospital.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.